Who are Oxycodone/Naloxone Prolonged Release's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): oxycodone naloxone tablet, Prolonged-release oxycodone/naloxone, Oxycodone/Naloxone Prolonged Release tablets, Oxycodone/Naloxone controlled-release.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxycodone-naloxone-prolonged-release.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Oxycodone/Naloxone Prolonged Release — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxycodone/Naloxone Prolonged Release (Oxycodone/Naloxone Prolonged Release) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic with abuse-deterrent formulation. Area: Pain Management.

marketed Opioid analgesic with abuse-deterrent formulation Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonism) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Oxycodone/Naloxone Prolonged Release (Oxycodone/Naloxone Prolonged Release) — Grünenthal GmbH. Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is included to reduce the potential for abuse by blocking opioid effects if the tablet is crushed and injected.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Oxycodone/Naloxone Prolonged Release TARGET	Oxycodone/Naloxone Prolonged Release	Grünenthal GmbH	marketed	Opioid analgesic with abuse-deterrent formulation	Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonism)
oxycodone naloxone tablet	oxycodone naloxone tablet	Mundipharma Research GmbH & Co KG	marketed	Opioid analgesic with abuse-deterrent formulation	Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonism)
Prolonged-release oxycodone/naloxone	Prolonged-release oxycodone/naloxone	Kati Järvelä	marketed	Opioid analgesic with abuse-deterrent formulation	Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonism)
Oxycodone/Naloxone Prolonged Release tablets	Oxycodone/Naloxone Prolonged Release tablets	Mundipharma Research GmbH & Co KG	phase 3	Opioid analgesic with abuse-deterrent formulation	Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonism)
Oxycodone/Naloxone controlled-release	Oxycodone/Naloxone controlled-release	Purdue Pharma LP	phase 3	Opioid analgesic with abuse-deterrent formulation	Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonist)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic with abuse-deterrent formulation class)

Mundipharma Research GmbH & Co KG · 2 drugs in this class
Grünenthal GmbH · 1 drug in this class
Kati Järvelä · 1 drug in this class
Purdue Pharma LP · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxycodone/Naloxone Prolonged Release — Competitive Intelligence Brief. https://druglandscape.com/ci/oxycodone-naloxone-prolonged-release. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing